Novo Nordisk Shares Plunge Following Disappointing Obesity Drug Trial Results
Novo Nordisk Shares Plunge Following Disappointing Obesity Drug Trial Results London, 23 February 2026 – Danish pharmaceutical giant Novo Nordisk has seen its share price drop by as much as 10% in European trading today. The slump follows the release of headline results from the REDEFINE 4 clinical trial, which revealed that the company’s experimental […]
Novo Nordisk Shares Plunge Following Disappointing Obesity Drug Trial Results Read More »
